Melanoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Solid Tumor (16716)

Ocular Melanoma (110)

Uveal Melanoma (105)

Cutaneous Melanoma (90)

Mucosal Melanoma (33)

Solid Tumor (16716)

Ocular Melanoma (110)

Uveal Melanoma (105)

Cutaneous Melanoma (90)

Mucosal Melanoma (33)

›

NRAS mutation	Melanoma	NRAS mutation	Melanoma	PDR001 + ERAS-254 Sensitive: C3 – Early Trials Eur J Cancer - 1 week (New C3) PDR001 + ERAS-254 Sensitive : C3 Eur J Cancer - 1wk	PDR001 + ERAS-254 Sensitive: C3 – Early Trials Eur J Cancer - 1 week PDR001 + ERAS-254 Sensitive : C3 Eur J Cancer - 1 week - (New C3)
CD52 overexpression	Melanoma	CD52 overexpression	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Pigment Cell Melanoma Res - 2 weeks (New C3) Immunotherapy Sensitive : C3 Pigment Cell Melanoma Res - 2wk	Immunotherapy Sensitive: C3 – Early Trials Pigment Cell Melanoma Res - 2 weeks Immunotherapy Sensitive : C3 Pigment Cell Melanoma Res - 2 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib + phenformin Sensitive: C3 – Early Trials Cancer Res Commun - 3 weeks (New C3) trametinib + dabrafenib + phenformin Sensitive : C3 Cancer Res Commun - 3wk	trametinib + dabrafenib + phenformin Sensitive: C3 – Early Trials Cancer Res Commun - 3 weeks trametinib + dabrafenib + phenformin Sensitive : C3 Cancer Res Commun - 3 weeks - (New C3)
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	Immunotherapy Sensitive: C3 – Early Trials SITC 2023 - 4 weeks (New C3) Immunotherapy Sensitive : C3 SITC 2023 - 4wk	Immunotherapy Sensitive: C3 – Early Trials SITC 2023 - 4 weeks Immunotherapy Sensitive : C3 SITC 2023 - 4 weeks - (New C3)
CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation	Melanoma	CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation	Melanoma	MRTX1719 Sensitive: C4 – Case Studies Cancer Discov - 4 weeks (New C4) MRTX1719 Sensitive : C4 Cancer Discov - 4wk	MRTX1719 Sensitive: C4 – Case Studies Cancer Discov - 4 weeks MRTX1719 Sensitive : C4 Cancer Discov - 4 weeks - (New C4)
BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	trametinib Resistant: A1 - Approval trametinib Resistant : A1	trametinib Resistant: A1 - Approval trametinib Resistant : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval nivolumab / relatlimab Sensitive : A1	nivolumab/relatlimab Sensitive: A1 - Approval nivolumab / relatlimab Sensitive : A1
BRAF V600 wild-type	Melanoma	BRAF V600 wild-type	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval nivolumab / relatlimab Sensitive : A1	nivolumab/relatlimab Sensitive: A1 - Approval nivolumab / relatlimab Sensitive : A1

Melanoma

Associations(1044)

Associations
(1044)